Anti-CD20 Antibody with Multimerized Fc Domains: A Novel Strategy To Deplete B Cells and Augment Treatment of Autoimmune Disease.

about

Anti-drug Antibodies Against a Novel Humanized Anti-CD20 Antibody Impair Its Therapeutic Effect on Primary Biliary Cholangitis in Human CD20- and FcγR-Expressing Mice

P2860

Q59137473-EE2D553C-A6B4-452E-BE28-341BEE77BD23

P2860

Anti-CD20 Antibody with Multimerized Fc Domains: A Novel Strategy To Deplete B Cells and Augment Treatment of Autoimmune Disease.

Item

http://www.wikidata.org/entity/Q40180170

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Anti-CD20 Antibody with Multim ...... eatment of Autoimmune Disease.

@en

type

Item

label

Anti-CD20 Antibody with Multim ...... eatment of Autoimmune Disease.

@en

prefLabel

Anti-CD20 Antibody with Multim ...... eatment of Autoimmune Disease.

@en

P1476

Anti-CD20 Antibody with Multim ...... reatment of Autoimmune Disease

@en

P2093

David S Block

http://www.w3.org/2001/XMLSchema#string

Edward So

http://www.w3.org/2001/XMLSchema#string

Emmanuel Y Mérigeon

http://www.w3.org/2001/XMLSchema#string

Erin Burch

http://www.w3.org/2001/XMLSchema#string

Henrik S Olsen

http://www.w3.org/2001/XMLSchema#string

Hua Zhou

http://www.w3.org/2001/XMLSchema#string

Scott E Strome

http://www.w3.org/2001/XMLSchema#string

Xiaoyu Zhang

http://www.w3.org/2001/XMLSchema#string

P2860

Complement is activated by IgG hexamers assembled at the cell surface.

Immunotherapeutic mechanisms of anti-CD20 monoclonal antibodies.

Drug insight: the mechanism of action of rituximab in autoimmune disease--the immune complex decoy hypothesis.

Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): considerably higher levels of CDC are induced by OFA than by RTX.

Macrophages eliminate circulating tumor cells after monoclonal antibody therapy

Therapeutic efficacy of intravenous immunoglobulin preparations depends on the immunoglobulin G dimers: studies in experimental immune thrombocytopenia.

Rituximab therapy and autoimmune disorders: prospects for anti-B cell therapy.

Tetramolecular immune complexes are more efficient than IVIg to prevent antibody-dependent in vitro and in vivo phagocytosis of blood cells.

Can antibodies with specificity for soluble antigens mimic the therapeutic effects of intravenous IgG in the treatment of autoimmune disease?

Intravenous immunoglobulin ameliorates ITP via activating Fc gamma receptors on dendritic cells.

P304

1165-1176

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4049/JIMMUNOL.1501755

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

196

http://www.w3.org/2001/XMLSchema#string

P50

Shaodong Chen

P577

2015-12-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

287995757

http://www.w3.org/2001/XMLSchema#string

P698

26695368

http://www.w3.org/2001/XMLSchema#string

Anti-CD20 Antibody with Multimerized Fc Domains: A Novel Strategy To Deplete B Cells and Augment Treatment of Autoimmune Disease.

about

P2860

P2860

Anti-CD20 Antibody with Multimerized Fc Domains: A Novel Strategy To Deplete B Cells and Augment Treatment of Autoimmune Disease.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P5875

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P5875

P698